A new class of cross-bridged cyclam-based macrocycles featuring phosphonate pendant groups has been developed. 1,4,8,11-tetraazacyclotetradecane-1,8-di(methanephosphonic acid) (CB-TE2P, 1) and 1,4,8,11-tetraazacyclotetradecane-1-(methanephosphonic acid)-8-(methanecarboxylic acid) (CB-TE1A1P, 2) have been synthesized and have been shown to readily form neutral copper(II) complexes at room temperature as the corresponding dianions. Both complexes showed high kinetic inertness to demetallation and crystal structures confirmed complete encapsulation of copper(II) ion within each macrocycle's cleft-like structure. Unprecedented for cross-bridged cyclam derivatives, both CB-TE2P (1) and CB-TE1A1P (2) can be radiolabeled with 64 Cu at room temperature in less than 1 h with specific activities >1 mCi mg -1 . The in vivo behavior of both 64 Cu-CB-TE2P and 64 Cu-CB-TE1A1P were investigated through biodistribution studies using healthy male Lewis rats. Both new compounds showed rapid clearance with similar or lower accumulation in non-target organs/tissues when compared to other copper chelators including CB-TE2A, NOTA and Diamsar.
Introduction
The quest for an optimal bifunctional chelator (BFC) continues to be one major goal in the research and development of metalbased radiopharmaceuticals for clinical imaging and therapeutic applications. An ideal BFC should bind the targeted radiometal with high specificity, yield, and with alacrity. Further, the resulting complex should be both thermodynamically stable and, more importantly, kinetically inert to in vivo transchelation or transmetallation processes. Copper-64 (T 1/2 = 12.7 h; b + : 0.656 MeV, 17.8%; b -: 0.573 MeV, 38.4%) is a promising radiometal with potential for applications in diagnostic imaging (positron emission tomography (PET)) and targeted radiotherapy.
1-3 It can also be produced in high yield and specific activity from a medical cyclotron. 4 Targeting 64 Cu(II), a variety of acyclic, macrocyclic, as well as macrobicyclic polyamine BFC's have been studied and reported.
2,5-10 Kinetic stability of Cu(II) complexes has been shown to be more predictive of in vivo stability than thermodynamic stability. 11 Macrocyclic chelators of Cu(II) such as TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11 -tetraacetic acid) demonstrated higher kinetic inertness and thus in vivo stability relative to acyclic chelators such as EDTA (ethylenediamine tetraacetic acid).
12,13
However, biodistribution and metabolism studies of 64 Cu-labeled TETA and TETA-biological molecule conjugates have revealed significant transchelation of 64 Cu to superoxide dismutase and metallothionein in liver and albumin in blood resulting in high background radioactivity.
14,15
We have previously developed a dicarboxymethyl pendant-armed cyclam macrocycle featuring an ethylene cross-bridge, CB-TE2A (4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane; Fig. 1 ), 16, 17 and shown that it possesses many of the desirable attributes to be an effective BFC for 64 Cu(II). ‡ The resulting radiolabeled complex 18 has been found to exhibit significantly improved in vivo behavior compared to non-cross-bridged analogs like TETA.
15,17,19- 21 We hypothesize that both its kinetic inertness to 64 Cu(II) loss and resistance to biological reduction contribute to these enhanced properties. CB-TE2A 9,17,20,22-25 and derivatives [26] [27] [28] [29] have been successfully bioconjugated to targeting peptides and investigated by us and other research groups.
A less-than-optimal aspect of the useful BFC CB-TE2A lies in the rather sluggish radio-copper binding kinetics necessitating relatively harsh labeling conditions (95
• C heating for 1-1.5 h) which can handicap its bioconjugation to more fragile targeting moieties. To overcome this limitation, we have developed a second generation of cross-bridged chelators incorporating methanephosphonic acid pendant arms. A number of phosphonate pendant-armed tetraazamacrocyclic chelators have been studied previously.
30-46
Substitution of methanephosphonic acid pendant arms for acetic acid functional groups has resulted in complexes having higher selectivity for Cu(II) and an increased thermodynamic and kinetic stability. 47 Radiochemistry, in vitro and in vivo stability, and biodistribution studies were reported for 64 Cu-labeled cyclen derivatives having 2, 3 or 4 methanephosphonate pendant arms (DO2P, DO3P and DOTP, respectively).
48 Cu(II)-DO2P was found to have a very high formation constant (logK = 28.7), while its 64 Cu-complex exhibited high in vitro stability in rat serum and a very rapid disappearance from the blood, liver and kidney. A higher bone uptake for 64 Cu-DO3P and 64 Cu-DOTP was observed, most likely due to the fact that methanephosphonate sidearms are known to have great affinity for the hydroxyapatite in the bone.
49-52
A side-bridged cyclam derivative with mixed phosphonate/acetate pendant arms, SB-TE1A1P (Fig. 1) , has also been reported, though heating was still required for high 64 Cu-labeling yields.
53
A related side-bridged phosphonate BFC precursor has also been reported.
54
Recently, we communicated in this journal the synthesis and characterization of the first methanephosphonic acid derivative of cross-bridged cyclam, CB-TE2P (1,4,8,11-tetraazacyclotetradecane-1,8-di(methanephosphonic acid), Fig.  1 ), its Cu(II) complex Cu-CB-TE2P, and 64 Cu(II) labeling and biodistribution studies. 55 Pleasingly, the anticipated acceleration of Cu(II) complexation was realized. However, the actual use of CB-TE2P as a BFC using conventional bioconjugation protocols is less straightforward. We have now prepared a mixedarmed variation, CB-TE1A1P (1,4,8,11-tetraazacyclotetradecane-1-(methanephosphonic acid)-8-(methanecarboxylic acid), Fig. 1 ), featuring both a methanephosphonic acid as well as a carboxymethyl pendant arm. We surmise that the former pendant arm will enhance the Cu(II) binding rate while the latter provides a scaffold to facilitate bioconjugation. In this report, we detail the synthesis and characterization of both CB-TE2P and CB-TE1A1P, and their respective copper(II) complexes, Cu-CB-TE2P and Cu-CB-TE1A1P. 56 Their 64 Cu-labeling along with biodistribution studies have also been carried out for comparison with other widely used BFC's including CB-TE2A, NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), and Diamsar (1,8-diamino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane) (Fig. 1 ).
Results and discussion

Ligand synthesis and characterization
As previously communicated, 55 CB-TE2P (1) was synthesized in two steps from cross-bridged cyclam 3 16 (Scheme 1(a)). 3 was first converted to bis-diethylphosphonate 4 by a variant of the Kabachnik-Fields three-component reaction 57-61 and this synthetic intermediate was then hydrolyzed to CB-TE2P. Thus, reaction of 3 with triethylphosphite and paraformaldehyde in anhydrous THF under nitrogen at room temperature for 4 days gave pure 4 in 94% yield after extractive workup. 4 was hydrolyzed in 6 M HCl under reflux for 24 h to give 1 in 64% yield as a hydrochloride after purification by ion exchange chromatography.
NMR spectroscopic results for this salt are similar to NMR spectra of previously studied di-inside-protonated salts of crossbridged ligands 62 and are consistent with a C 2 -symmetric diamond-lattice [2323]/[2323] conformation 16,63,64 for the bicyclic backbone in solution, which is the conformation that has been observed in the solid state for such cross-bridged salts. 62 In the 1 H NMR spectrum, every geminal pair of hydrogens is diastereotopic and anisochronous and exhibits the coupling patterns and coupling constants expected of an equatorial/axial pair of hydrogens in a diamond-lattice arrangement (see the Experimental for detailed interpretation and the ESI for spectra †). However, neither a related non-diamond-lattice [2233]/[2233] conformation, which differs from the former by a change in sign of the crossbridge N-C-C-N torsion angle, nor a time-averaged dynamic mixture of these two conformations in solution can be rigorously excluded as possibilities. Nevertheless, we were surprised when an X-ray crystal structure of 1·HCl·4H 2 O (Fig. 2 diamond-lattice conformation. A possible explanation for this observation lies in the fact that net-positively-charged di-insideprotonated ligand possesses one phosphonic acid arm and one phosphonate arm and these are shown to be intramolecularly O-H ◊ ◊ ◊ O hydrogen bonded (disordered) in the solid state. This conformation of the ligand backbone may be necessary in order to facilitate the appropriate arm-arm distance for the intramolecular H-bond. In aqueous solution, solvation of phosphonate arms would likely dominate over arm-arm intramolecular H-bonding, so the diamond-lattice backbone conformation may be favored in solution.
Fig. 2 X-ray structure of 1·HCl·4H 2 O (50% thermal ellipsoids for all non-hydrogen atoms). Intramolecular hydrogen bonds are shown as dashed lines. One of the two half-occupancy symmetry-related hydrogens on O2 has been removed for clarity so that the H-bond can be shown.
CB-TE1A1P (2) was synthesized similarly in two steps from the previously reported unsymmetrical synthetic intermediate CB-TE1A tert-butyl ester 5 (Scheme 1(b)).
19 5 was reacted with triethylphosphite and paraformaldehyde in anhydrous THF for 4 days at room temperature to give, after an extractive workup, the corresponding phosphonate ester 6, which was taken on to the next step without further purification. Hydrolysis of both the diethylphosphonate and tert-butyl carboxylic ester moieties of 6 was accomplished in refluxing 6 M HCl to give 2 in 62% overall (two step) yield from 5 as a hydrochloride salt after purification by ion exchange chromatography (Scheme 1 (b) 
Synthesis and characterization of copper(II) complexes of CB-TE2P and CB-TE1A1P
The Cu(II) complex of CB-TE2P was initially prepared from CuCl 2 and the ligand in refluxing methanol with the pH adjusted to 8 using aqueous NaOH. Subsequently, it was found that complexation in methanol was already complete in less than 5 min at ambient temperature. The blue complex has a d-d absorption maximum at l max (MeOH)/nm 639 (e/dm 3 mol -1 cm -1 35). Its cyclic voltammogram in 0.1 M aq. NaOAc exhibited a quasireversible reduction at -0.96 V (Ag/AgCl), typical of Cu(II) crossbridged cyclam complexes. Its acid inertness was assayed under pseudo first-order conditions in 5 M HCl at 90
• C and found to have a half life of 3.8(1) h. While this is much less impressive than the 154 h previously reported for Cu-CB-TE2A, it is nonetheless significantly more inert than both Cu-DOTA and Cu-TETA which completely decomplexed within minutes.
As desired, the complexation of copper(II) by CB-TE1A1P also proceeded readily at room temperature even in acidic aqueous solution. The isolated dark-blue complex exhibited a carboxylate stretching band at 1619 cm -1 in its IR spectrum and a d-d band maximum at 613 nm (e/dm 3 mol -1 cm -1 24) in its electronic spectrum. In contrast to previously reported cross-bridged cyclam copper(II) complexes including Cu-CB-TE2P, the electrochemical reduction of Cu-CB-TE1A1P has been found to be irreversible with a peak potential at around -1.0 V (Ag/AgCl) accompanied by a large copper stripping peak in the reverse scan. Acid inertness studies of the complex in 5 M HCl at 90
• C gave a half-life of 6.8(1) h which is comparable to Cu-CB-TE2P though both are significantly less acid-resistant than Cu-CB-TE2A (half-life = 154(6) h).
X-ray structures of Cu-CB-TE2P and Cu-CB-TE1A1P
The X-ray crystal structure of Cu-CB-TE2P 55 is shown in Fig. 3 The X-ray structure of Cu-CB-TE1A1P also has the expected full six-coordinate N 4 O 2 envelopment of the cation with the methylphosphonate arm monoprotonated to give a charge-neutral complex overall (Fig. 4) . The Jahn-Teller elongation here is found along the O(1)-Cu(1)-N(2) axis with the phosphonate Cu-O 2.544(3) Å and Cu-N 2.220(3) Å . In comparison, the Cu(1)-O(4) bond to the carboxylate oxygen is much shorter at 1.993(2) Å . It should be noted that each phosphonate P(O)OH moiety is hydrogen bonded to the P(O)OH of another complex in a dimeric structure, so it may be that the weaker phosphonate coordination and apparent Jahn-Teller elongation is partly a consequence • indicates that the cation is slightly sunken into the ligand cleft. Again, the ligand here adopts the [2233]/[2233] conformation suggesting that methanephosphonate pendant arms, with their longer P-C and P-O bonds compared to the C-C and C-O bonds of acetate arms, may dictate this optimum cross-bridged cyclam conformation for Cu(II) binding. Alternatively, the conformations may be similar enough in energy that solvation or packing effects could determine the preference.
Significant bonding data for both complexes are listed for comparison in Table 1 . To sum up the structural results, both CB-TE2P and CB-TE1A1P have been shown to readily form sixcoordinate copper(II) complexes at ambient temperature resulting in full envelopment of the cation by the respective chelator. Each of these complexes adopts the more unusual [2233]/[2233] conformation in the solid state. Our assays of these products further confirmed that both should be sufficiently inert to acid Table 1 Comparison of bond lengths and angles in Cu-CB-TE2P and Cu-CB-TE1A1P
Cu-CB-TE2P
Cu-CB-TE1A1P
Bond distances in Å and bond angles in (
decomplexation and resistant to reduction by common biological reductants.
Density Functional Theory (DFT) MO calculations on Cu-CB-TE2A, Cu-CB-TE2P and Cu-CB-TE1A1P
The structural results (vide supra) led us to investigate whether the preference of Cu-CB-TE2P and Cu-CB-TE1A1P for the 77 In each case, the all-electron 6-31G* basis set was employed and geometry optimization was carried out (E, kcal mol -1 ). Furthermore, in each case a frequency calculation was carried out so that zero-point energy (ZPE) corrections could be made (E corr , kcal mol -1 ) and free energies (G, kcal mol -1 at 298 K) could be calculated. In the case of the M06 functional, single-point calculations at the M06/6-31+G**//M06/6-31G* level were also carried out for both conformations of all three complexes. The results (energies in kcal mol -1 ) are summarized in Table 2 . Inspection of the relative (gas phase) ZPE-corrected energies and free energies in Table 2 show that the calculations using the more reliable M06 functional qualitatively reproduce the relative conformational energies implied by the crystallographic results. The M06/6-31G*//M06/6-31G* calculations show the [2233]/[2233] conformer to be more stable for CB-TE2P and CB-TE1A1P and the [2323]/[2323] conformer to be favored for CB-TE2A. The single point M06/6-31+G**//M06/6-31G* energy differences are not significantly different from the lower level basis E differences for Cu-CB-TE2P and Cu-CB-TE1A1P. The gap Table 2 DFT energetic results for conformers of Cu-CB-TE2P, Cu-CB-TE1A1P, and Cu-CB-TE2A
Cu-CB-TE2P B3LYP/6-31G*//B3LYP/6-31G*:
Relative energies (kcal mol 
Radiolabeling of CB-TE2P and CB-TE1A1P
Even though cold chemistry experiments showed that the copper(II) complexes of CB-TE1A1P and CB-TE2P formed quickly and under mild conditions in organic solvents (e.g., methanol), radiochemistry experiments were performed in aqueous solvents for translation to in vivo investigations. Radiolabeling reactions of 64 Cu to CB-TE2P and CB-TE1A1P were performed under aqueous conditions with various buffers, pH values (4.5-8.1), and temperatures • C). The radiolabeling yield was determined by radio-HPLC, with the free 64 Cu having a retention time of~4 min and the 64 Cu complexes having a retention time of~20 min. The HPLC peaks corresponding to 64 Cu-CB-TE1A1P and 64 Cu-CB-TE2P were assigned by LC-MS of a carrier-added sample. Note that under no carrier-added conditions the concentration of the 64 Cu complexes was too low to be detected by either UV or MS. Using mM concentrations of CB-TE2P or CB-TE1A1P, radiolabeling was complete under 1 h, but only at higher temperatures or with carrier-added Cu(II). Using mM concentrations, the CB-TE2P and CB-TE1A1P were labeled with 64 Cu at room temperature in shorter time periods. The optimized conditions for 64 Cu-labeled CB-TE1A1P and CB-TE2P were as follows: 100 mL of a 26.5 mM solution of chelator in 0.1 M NH 4 OAc (pH = 8.1) was incubated with 1 mCi of 64 CuCl 2 at room temperature. Radiochemical yields of >95% were achieved after 30 min. This was the first successful attempt to efficiently radiolabel cross-bridged cyclam derivatives at room temperature. Copper-64-labeling of CB-TE2A under the same conditions resulted in negligible radiochemical yields. As previously reported, CB-TE2A requires temperatures >90
• C in order to achieve complete radiolabeling within 1 h.
18
Biodistribution studies of 64 Cu-CB-TE2P and 64 
Cu-CB-TE1A1P
In order to gain insight into the pharmacokinetics of the 64 Culabeled complexes, biodistribution studies were performed. 64 Cu-CB-TE2P and 64 Cu-CB-TE1A1P (50 mCi (~1 mCi mg -1 ) in 150 mL of saline) were injected through the tail vein in male, Lewis rats (26 d). The animals were sacrificed at 1, 2, 4 and 24 h after injection, the organs were harvested, and their activity measured with a g counter. The radiolabeled compounds that were injected for biodistribution studies were positively identified as 64 Cu-CB-TE2P and 64 Cu-CB-TE1A1P by LC-MS and radio-LC-MS, and were compared to an authentic standard under carrier-added conditions.
As discussed in our communication, 55 64 Cu-CB-TE2P clears rapidly from the blood (from 0.15%ID g -1 at 1 h to 0.002%ID/g at 24 h) and has only minor residual uptake in non-target organs such as liver, spleen, lung, heart and marrow (not higher than 0.03%ID g -1 at 24 h). Rapid clearance of 64 Cu-CB-TE2P from the liver was indicative of its high in vivo stability, as it is known that dissociated 64 Cu is rapidly coordinated by liver proteins such as superoxide dismutase (SOD), ceruloplasmin and metallothionein and is retained in liver, kidneys and the blood circulation.
A biodistribution study of 64 Cu-CB-TE1A1P in Lewis rats (Fig.  5 ) demonstrated rapid blood clearance (0.08 ± 0.02%ID g -1 at 1 h postinjection) and low liver accumulation (0.11 ± 0.01%ID g -1 at 1 h postinjection), suggesting that 64 Cu-CB-TE1A1P had comparable stability to 64 Cu-CB-TE2A and 64 Cu-CB-TE2P in vivo. Higher uptake was observed in the kidney (1.20 ± 0.43%ID g -1 at 1 h postinjection which decreased to 0.30 ± 0.03%ID g -1 at 24 h), while no significant uptake was detected in lung, spleen, heart or stomach. These data suggest that 64 Cu-CB-TE1A1P clears quickly through the kidneys, with a marginal amount clearing through the liver. Bone uptake cleared significantly by 24 h (0.19 ± 0.04%ID g -1 and 0.044 ± 0.003%ID g -1 at 1 and 24 h postinjection, respectively). Overall, the biodistribution of CB-TE1A1P was similar to that of CB-TE2P, except for a lower accumulation in the bone at all time points (p < 0.0001). Note that unlike the recentlyreported 4,11-dimethyl-cyclam-1,8-bis(methylphosphonic acid),
41
both CB-TE2P and CB-TE1A1P form Cu(II) complexes that are suitable for radiopharmaceutical applications because of their inertness in vivo, a direct consequence of the cross-bridged bicyclic structure. CB-TE1A1P ( ᭺ ) from blood, marrow, liver and kidney. 64 Cu-NOTA showed significantly higher liver retention (0.086 ± 0.01%ID g -1 ), while 64 Cu-Diamsar has higher kidney retention (1.75 ± 0.50%ID g -1 ) compared to the other complexes (24 h postinjection; p < 0.0005). Overall, 64 Cu-CB-TE2P and 64 Cu-CB-TE1P demonstrated significantly, but not dramatically, higher accumulations in the marrow, liver and kidneys than 64 Cu-CB-TE2A (p < 0.05). However, 64 Cu-CB-TE2P and 64 Cu-CB-TE1P had significantly lower accumulations in the marrow than 64 CuDiamsar and 64 Cu-NOTA, and significantly more clearance from the blood compared to 64 Cu-NOTA (p < 0.05). These results are important since CB-TE2P and CB-TE1A1P maintain most of the positive attributes of CB-TE2A including high in vivo stability of the 64 Cu-complexes; however, a major advantage is that they can be quantitatively labeled at room temperature. 64 Cu-CB-TE2A has been shown to have unparalleled in vivo stability that is much higher than the commonly used DOTA and TETA chelators. However, the high temperatures required for labeling CB-TE2A with 64 Cu have limited its conjugation to only robust peptides and small molecules. CB-TE1A1P will likely eliminate this restriction and allow for its broader use in 64 Cu labeling of all types of targeting molecules, including temperaturesensitive proteins such as monoclonal antibodies.
Along with in vivo stability, charge and lipophilicity likely play a role in the difference in liver and kidney uptake. For example, the neutral 64 Cu-CB-TE2A complex has the highest liver uptake at 1 h post-injection, but has the most extensive clearance of the five complexes, likely due to its superior in vivo stability. 64 Cu-diamsar, which has a 2+ charge, has the highest retention in the kidneys, and this is consistent with positively charged metal complexes being retained in the kidneys. 78 The macrocycles with the phosphonate pendant arms as well as the NOTA complex of 64 Cu(II) are all negatively charged, and thus clear rapidly from the liver and kidneys. To our knowledge, charge does not have a significant impact on blood clearance or retention in the bone marrow.
It is important to emphasize that these data with the 64 Cuchelates may not predict with certainty the in vivo stability with 64 Cu-labeled chelator-biomolecule conjugates, as the linkage between the chelator and the biomolecule, as well as the nature of the biomolecule have a significant impact on biodistribution. Conjugation of CB-TE1A1P to a biomolecule will result in the conversion of the carboxylate group to an amide moiety. We previously demonstrated that the amide oxygen decreases in vivo stability compared to the carboxylate group, and this may negatively impact stability of a CB-TE1A1P-biomolecule conjugate. However, preliminary data from the Anderson lab 79 has demonstrated that a 64 Cu-labeled CB-TE1A1P conjugate of the somatostatin analog, Y3-TATE, has a similar biodistribution to 64 Cu-CB-TE2A-Y3-TATE, 17 including blood and liver clearance. Maecke et al. compared 64 Cu-labeled NOTA and CB-TE2A analogs of a somatostatin antagonist, LM3, and a a v b 3 integrin-targeted RGD peptide in tumor-bearing mouse models.
80, 81 Interestingly, the 64 Cu-labeled NOTA (NODAGA) LM3 conjugate showed significantly higher tumor : non-target tissue ratios compared to 64 Cu-CB-TE2A-LM3; 80 however, for RGD, the CB-TE2A conjugates showed higher tumor : blood and tumor : liver ratios at 18 h postinjection. 81 This underscores the likelihood that there is not one single Cu(II) chelator that is optimal for all biomolecules.
Summary and conclusions
A new class of cross-bridged cyclam macrocycles having methanephosphonic acid pendant arms has been developed. These compounds readily formed copper(II) complexes and the 64 Culabeled chelates demonstrate promising kinetic inertness in vivo. . DFT calculations reproduce this conformational change, which may be a consequence of the longer C-P and P-O bonds in the phosphonate arms as compared to the C-C and C-O bonds of the acetate arms. Acid inertness and electrochemical assays support the viability of these cross-bridged complexes in vitro. Biodistribution of 64 Cu-CB-TE2P and CB-TE1A1P in normal rats show comparable in vivo stability to the current "gold standard", 64 Cu-CB-TE2A, but they both have the major advantage of being amenable to 64 Cu labeling at room temperature with high specific activity. CB-TE2P and CB-TE1A1P are the first examples of cross-bridged cyclam derivatives that can be radiolabeled with 64 Cu at room temperature under no-carrier-added conditions. CB-TE1A1P has the potential for enabling the design of a new generation of imaging agents that can be quickly labeled at room temperature and with high stability in vivo, expanding the portfolio of potential agents beyond heatstable small molecules and peptides into heat-sensitive proteins such as monoclonal antibodies. Bioconjugation of CB-TE1A1P and associated radiolabeling and biological studies toward cancer diagnosis will be reported in future publications. UV-Vis spectra were obtained on a Varian Cary 50 spectrophotometer. Electrochemical studies were performed on a BAS 100B electrochemical analyzer in 0.1 M aq. NaOAc solution using a glassy carbon working electrode, a platinum wire auxiliary electrode, and Ag/AgCl reference electrode. Acid inertness studies were carried out under pseudo first-order conditions in 5 M HCl solutions at 90
Experimental Materials and methods
Reagents
• C by monitoring the time-dependent decay of the electronic absorption maximum at 630 nm.
Ligand synthesis
CB-TE2A was synthesized as previously published.
16,17
Diamsar 82-84 and NOTA 85 were synthesized as described in the literature. 4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-bis(methanephosphonic acid diethyl ester) (4) . Triethyl phosphite (0.18 mL, 1.0 mmol) and paraformaldehyde (32.5 mg, 2.5 molar equivalents of CH 2 O) were added to a solution of 1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (3) (0.0982 g, 0.4338 mmol) in 1.5 mL of dry THF and stirred under N 2 for 4 days. The solvent was removed, the residue was dissolved in H 2 O (20 mL), and the solution was made strongly basic (pH = 14, slow addition of KOH pellets). The resulting solution was extracted with toluene (5 ¥ 11 mL), the combined organic phases were dried over anhyd. Na 2 SO 4 , the solvent was removed under aspirator pressure, and the residual solvent was removed under vacuum to give NMRpure product (0.2156 g, 94%) as a waxy white solid 4: mp 42-44 19 (5, 30 mg, 0.088 mmol) in dry THF (2 mL) and stirred under N 2 for 4 days. The solvent was removed, the residue was dissolved in H 2 O (10 mL), and the solution was made strongly basic (pH = 14, slow addition of KOH pellets). The resulting solution was extracted with toluene (3 ¥ 10 mL) and CH 2 Cl 2 (3 ¥ 10 mL), the combined organic phases were dried over anhyd. Na 2 SO 4 , the solvent was removed under reduced pressure, and the residual solvent was removed under vacuum to give reasonably pure product by NMR (35 mg, 81%) The reaction was also scaled up and the product carried directly to the next step: Triethyl phosphite (0.18 mL, 1.0 mmol) and paraformaldehyde (32.5 mg, 2.5 molar equivalents of CH 2 O) were added to a solution of 5 (200 mg, 0.587 mmol) in dry THF (4 mL) and stirred under N 2 for 4 days. Solvent was removed, the residue was dissolved in H 2 O (20 mL), and the solution was made strongly basic (pH = 14, slow addition of KOH pellets). The resulting solution was extracted with toluene (5 ¥ 20 mL), the combined organic phases were dried over anhyd. Na 2 SO 4 , and solvent was removed to give crude product (0.29 g, oil) that was used for the next reaction without further purification. 29 g ) from the previous step was dissolved in 35 mL of 6 M HCl and refluxed under N 2 for 1 day. The solvent was removed under reduced pressure and the crude product was dissolved in 4 mL of H 2 O and chromatographed using a weakly acidic cation exchange column (Amberlite CG50, H + form, 7.7 g, column size = 27 cm ¥ 2 cm). The product was eluted with H 2 O (first 30 mL of eluant was discarded), fractions containing the product were combined (35 fractions, 3 mL each), the solvent was removed under reduced pressure, and residual solvent was removed under vacuum to give the desired product as a white solid hydrated hydrochloride (0.157 g, 0.365 mmol, 62% yield from 5): mp >250
1,
• C. 1.86 (1 H, dm, J 16.9, 13-H eq ), 2.33-2.45 (2 H, m, 6-H Cu-CB-TE1A1P. An amount of CB-TE1A1P·0.45HCl·2H 2 O (84 mg, 0.19 mmol) was dissolved in 2 mL water along with Cu(ClO 4 ) 2 ·6H 2 O (75 mg, 0.20 mmol). The solution pH was adjusted to 2 using 0.1 N NaOH and stirred for 1 h. After removal of solvent by rotary evaporation, the blue residue was dissolved in 1 mL of methanol. After a small amount of insoluble material was removed by centrifugation, the supernatant was placed in a vial inside a chamber and diethyl ether allowed to diffuse into it. After 2 days, a dark-blue solid deposited which was separated and dried. About 1 mL of hexafluoro-isopropanol was added to this solid and the resulting suspension centrifuged to remove a small amount of insoluble matter. The supernatant was returned to the ether diffusion chamber yielding a darkblue solid product (120 mg, 95% yield) upon standing. : reduction peak potential -1.03 V (irrev, Ag/AgCl), copper stripping peak +0.10 V. Crystals suitable for X-ray diffraction study were obtained by slow evaporation of a 6 M aqueous ammonia sample solution.
X-ray structural studies
A summary of crystal data for the two X-ray structures can be found in Table 3 .
Cu-CB-TE2P. A crystal was mounted on a Cryoloop with Paratone-N oil and cooled to -173
• C under a stream of dry nitrogen gas. Data were collected on a BRUKER APEX2 CCD X-ray system using Cu K alpha radiation at -173
• C and integrated using APEX2 software (SHELXL) corrected for adsorption using SADABS. Structure was solved by direct methods and all nonhydrogen atoms were refined as being anisotropic. Two molecules were found in the asymmetric unit. One of the molecules was disordered and this was treated by assuming a two-position disorder model. Although all the hydrogen atoms were not found, they were included in the chemical formula to account for F000, density and molecular weight.
Disorder associated with Cu-CB-TE2P was treated by using a 50% occupancy model for atoms C15, C16, C17, C18, C23, C24, C25, C26, C27, N5, N6, O7, O8, O9, P3, O2SA, O2SB, O6SA, O6SB, C15¢, C16¢ C17¢, C18¢, C23¢, C24¢, C25¢, C26¢ C27¢, N5¢, N6¢, O7¢, O8¢, O9¢, P3¢ and their associated hydrogen atoms. Occupancies were set for the following atoms at values indicated: Atoms O5SA 40%, O5SB 60%, O7SA and O7SB both at 30% occupancy while O7SC was at 40% occupancy; atoms Na1A and Na1B 75% and 25%, respectively. The hydrogen atoms on O8 and O8¢ were fixed in position with appropriate riding models.
Cu-CB-TE1A1P. A blue crystal was mounted on a Cryoloop with Paratone-N oil. Data were collected on a Bruker APEX II CCD system using Mo K alpha radiation in a nitrogen gas stream at 100(2) K using phi and omega scans. Crystal-to-detector distance was 60 mm and exposure time was 10 s per frame using a scan width of 0.5
• . Indexing and unit cell refinement indicated a primitive, orthorhombic lattice. The space group was found to be Pccn. The data were integrated using the Bruker SHELXTL software program and scaled using the SADABS software program. Solution by direct methods (SHELXS) and all non-hydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-97). All hydrogen atoms except H2P on O2 were placed on their appropriate parent atom using a riding model. Hydrogen H2P was determined from a Fourier difference map and was allowed to refine. Hydrogen atoms on water molecules were restrained using DFIX and DANG commands. 64 Cu-NOTA, 64 Cu-Diamsar, 64 Cu-CB-TE2P or 64 Cu-CB-TE1A1P (40-60 mCi; 0.5-130 nmol ligand) intravenously via the tail vein. Tissue biodistribution data were obtained at 1, 4, and 24 h postinjection. Animals were sacrificed at 1, 4 and 24 h postinjection, organs of interest were removed, weighed, and counted on a gamma counter (Beckman). The percent injected dose per gram (%ID g -1 ) and percent injected dose per organ (%ID organ -1 ) were measured by comparison against a weighed, counted standard.
Computational chemistry
All DFT calculations were carried out in parallel mode using Spartan'10 version 1.1.0 (Wavefunction, Inc., Irvine, CA) running the Q-Chem computational engine 87 on a Mac Pro dual QuadCore Intel Xeon (2.93 GHz) computer with 16 GB of RAM.
